Da-Yong Lu.jpg

Contributed Article: Drug Combination in Clinical Cancer Treatments”


Testimonial by Da-Yong Lu!

Da-Yong Lu

Contributed Article: “Drug Combination In Clinical Cancer Treatments

Highlighted Article – Evaluation of Salivary Melatonin Levels in HIV- Positive Patients – Reviews on Recent Clinical Trials

RRCT-Articles_12-4-Fatemeh Ahmadi-Motamayel


Most Accessed Article – Neoadjuvant Therapy for HER2-positive Breast Cancer – Reviews on Recent Clinical Trials

Journal: Reviews on Recent Clinical Trials

Author(s): Rachel Wuerstlein, Nadia Harbeck.

Graphical Abstract:



In HER2-positive early breast cancer, neoadjuvant treatment with a combination of sequential chemotherapy and HER2-targeted therapy is currently the standard of care. This is followed by breast surgery, radiotherapy (if indicated), completion of 12 months of HER2-directed therapy, and – depending on the tumor biology – endocrine adjuvant therapy, and ultimately follow up.

10-year survival rates in the HER2-positive subgroup of breast cancer do reach now more than 75% with the introduction of first adjvuant and later neoadjuvant HER2-targeted therapies over the last 15 years. The neoadjvuant setting helps to downstage locally advanced tumors, to provide early information of tumor response, to assess the efficacy of new therapies in vivo, to reduce treatment duration, and to introduce new targeted therapies into the clinical routine. It also allows enrolling fewer patients into clinical trials in order to reach adequate effects in clinical outcome.

The neoadjuvant approach and our interest in this setting are based on pCR (pathological complete response) and its translation into better long-term outcome. In recent trials, we have reached more than 60% pCR with a subsequent improvement of DFS and hopefully OS. Therefore, chemotherapy schedules and new HER2-targeted agents such as lapatinib, pertuzumab, and T-DM1 have been introduced into the neoadjuvant setting. To balance over- and undertreatment, current trials include personalized concepts and assess new biomarkers and tumorbiological factors. We have learned for example to differentiate between HR (hormone receptor)-positive and -negative tumors in the HER2-positive population. Depending on pCR or non-pCR after neoadjuvant treatment, the adjuvant therapy may be adjusted. This concept of post-neo-adjuvant trials is now entering the field of strategies in the neoadjuvant setting for HER2-positive non-metastatic primary breast cancer.
The 2017 standard of care in the neoadjuvant setting according to national and international guidelines combines a taxane-containing chemotherapy with a dual blockade of trastuzumab and pertuzumab.
This review will point out current trials and their strategies to continue improving outcome and reduce morbidity as well as mortality in HER2-positive early breast cancer.

Article by Disease – “Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature”

Article by Disease on “Oncology

Graphical Abstract:



Background: To assess the role of early palliative care in patients with advanced oncologic and non-oncologic chronic diseases.

Methods: A qualitative systematic review of literature was performed. All the randomized phase III trials comparing early, simultaneous palliative care and standard care in patients with advanced oncologic and non-oncologic diseases were considered eligible and included into the analysis. The outcomes were classified into 6 classes: quality of life, symptoms control, overall survival, quality of care, patients’ and caregivers’ satisfaction, and costs of the assistance.

Results: Twelve papers reporting the data of 9 trials were considered eligible and included into the analysis. Two nonrandomized trials were also included into the selection because of the methods used by the authors. The early, simultaneous approach was reported to improve quality of life in two out of 7 papers, symptoms control in 1 out of 5 papers, overall survival in 2 out of 3 papers, quality of care in 5 out of 8 papers, patients’ or caregivers’ satisfaction in 3 out of 4 papers; and to reduce the costs of assistance in 2 out of 3 papers.

Conclusion: Early palliative care improves the main outcomes of the assistance in patients with advanced oncologic and non-oncologic chronic diseases. The available data are probably enough to consider early palliative cares a novel standard of care in these groups of patients.

Read more: http://www.eurekaselect.com/node/135802/article

New Issue :: Reviews on Recent Clinical Trials 12, Issue 1

Reviews on Recent Clinical Trials publishes frontier reviews, original research articles, drug clinical trial studies and guest edited thematic issues on recent clinical trials of major importance. The journal’s aim is to publish the highest quality articles in the field. Topics covered include: important Phase I – IV clinical trial studies, clinical investigations at all stages of development and therapeutics.

The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.


Articles from the journal Reviews on Recent Clinical Trials 12, Issue 1:

For details on the articles, please visit this link :: http://bit.ly/2lV1Frp

Highlighted Article Flyer for the journal “Reviews on Recent Clinical Trials”



%d bloggers like this: